Jesús Alberto Afonso Urich

Mr. Jesús Alberto Afonso Urich

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SESimone Eder
Simone Eder
LWLaura Wiltschko
Laura Wiltschko
IKIoannis Koutsamanis
Ioannis Koutsamanis
JUJesús Alberto Afonso Urich
Jesús Alberto Afonso Urich
FAFlorian Arbeiter
Florian Arbeiter
MSMartin Spoerk
Martin Spoerk

8 July 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
EFElisabeth Fink
Elisabeth Fink
SCSelma Celikovic
Selma Celikovic
JRJakob Rehrl
Jakob Rehrl
SSStephan Sacher
Stephan Sacher
JUJesús Alberto Afonso Urich
Jesús Alberto Afonso Urich
JKJohannes Khinast
Johannes Khinast

1 December 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SSStephan Sacher
Stephan Sacher
NHNikolaus Heindl
Nikolaus Heindl
JUJesús Alberto Afonso Urich
Jesús Alberto Afonso Urich
JKJulia Kruisz
Julia Kruisz
JKJohannes G. Khinast
Johannes G. Khinast

1 December 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CCCarolina Corzo
Carolina Corzo
AFAgnes Fuchsbichler
Agnes Fuchsbichler
ISIoana Savencu
Ioana Savencu
JUJesús Alberto Afonso Urich
Jesús Alberto Afonso Urich
AZAndreas Zimmer
Andreas Zimmer
Sharareh Salar-BehzadiSharareh Salar-Behzadi
Sharareh Salar-Behzadi

3 July 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CCCarolina Corzo
Carolina Corzo
DCDjana Crvenjak
Djana Crvenjak
KSKamen Sotirov
Kamen Sotirov
JUJesús Alberto Afonso Urich
Jesús Alberto Afonso Urich
KÖKristin Öhlinger
Kristin Öhlinger
Sharareh Salar-BehzadiSharareh Salar-Behzadi
Sharareh Salar-Behzadi

24 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMartin Spoerk
Martin Spoerk
IKIoannis Koutsamanis
Ioannis Koutsamanis
JMJosip Matić
Josip Matić
SESimone Eder
Simone Eder
CZCarolina Patricia Alva Zúñiga
Carolina Patricia Alva Zúñiga
APAmrit Paudel
Amrit Paudel
To avoid any type of cross-contamination, residue-free production equipment is of utmost importance in the pharmaceutical industry. The equipment cleaning for continuous processes such as hot melt extrusion (HME), which has recently gained popularity in pharmaceutical applications, necessitates extensive manual labour and costs. The present work tackles the HME cleaning issue by investigating two cleaning strategies following the extrusion of polymeric formulations of a hormonal drug and for a sustained release formulation of a poorly soluble drug. First, an in-line quantification by means of UV–Vis spectroscopy was successfully implemented to assess very low active pharmaceutical ingredient (API) concentrations in the extrudates during a cleaning procedure for the first time. Secondly, a novel in-situ solvent-based cleaning approach was developed and its usability was evaluated and compared to a polymer-based cleaning sequence. Comparing the in-line data to typical swab and rinse tests of the process equipment indicated that inaccessible parts of the equipment were still contaminated after the polymer-based cleaning procedure, although no API was detected in the extrudate. Nevertheless, the novel solvent-based cleaning approach proved to be suitable for removing API residue from the majority of problematic equipment parts and can potentially enable a full API cleaning-in-place of a pharmaceutical extruder for the first time.